Abstract
Research in new treatments for schizophrenia continues. At the same time, increasing numbers of persons with schizophrenia receive their treatment almost exclusively in correctional settings. Though the literature continues to describe this phenomenon in clearer detail, many questions regarding the characteristics of these mentally disordered offenders and their unique treatment needs remain. Research targeting this growing subset of persons with schizophrenia is limited. Risk factors that lead the person with schizophrenia into the correctional system, and whether the offenders with schizophrenia actually differ from non-offenders in terms of their psychopharmacological needs are significant questions that remain unaddressed. Countertransference towards the offender remains a significant issue as well. Given the many limitations on research in this population, pharmacologic strategies for the offender population must be extrapolated from the non-offender population. Traditional depot neuroleptics continue to be underutilized in the treatment of this population. It is argued that both traditional and forthcoming atypical depot neuroleptics may be the best first line agents in this population.
Keywords: Schizophrenia, psychopharmacological, Countertransference, neuroleptics
Current Pharmaceutical Design
Title: Treatment Considerations in the Forensic Patient with Schizophrenia
Volume: 10 Issue: 18
Author(s): David C. Stone and David O. Niz
Affiliation:
Keywords: Schizophrenia, psychopharmacological, Countertransference, neuroleptics
Abstract: Research in new treatments for schizophrenia continues. At the same time, increasing numbers of persons with schizophrenia receive their treatment almost exclusively in correctional settings. Though the literature continues to describe this phenomenon in clearer detail, many questions regarding the characteristics of these mentally disordered offenders and their unique treatment needs remain. Research targeting this growing subset of persons with schizophrenia is limited. Risk factors that lead the person with schizophrenia into the correctional system, and whether the offenders with schizophrenia actually differ from non-offenders in terms of their psychopharmacological needs are significant questions that remain unaddressed. Countertransference towards the offender remains a significant issue as well. Given the many limitations on research in this population, pharmacologic strategies for the offender population must be extrapolated from the non-offender population. Traditional depot neuroleptics continue to be underutilized in the treatment of this population. It is argued that both traditional and forthcoming atypical depot neuroleptics may be the best first line agents in this population.
Export Options
About this article
Cite this article as:
Stone C. David and Niz O. David, Treatment Considerations in the Forensic Patient with Schizophrenia, Current Pharmaceutical Design 2004; 10 (18) . https://dx.doi.org/10.2174/1381612043384079
DOI https://dx.doi.org/10.2174/1381612043384079 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Photoactivatable Platinum Complexes
Anti-Cancer Agents in Medicinal Chemistry Survival Factors from Activated Accessory Cells and their Role in Triggering Autoimmune Diseases
Current Medicinal Chemistry Oxidative Stress and Neurodegenerative Diseases: A Neurotrophic Approach
Current Drug Targets The TOLL-like / Type-I Interferon Pathways as Emerging Therapeutic Targets for Autoimmune Diseases
Drug Design Reviews - Online (Discontinued) Differentiating Normal from Pathological Brain Ageing Using Standard Neuropsychological Tests
Current Alzheimer Research Anticancer Vitamin K3 Analogs: A Review
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Effects of Progesterone in Animal Models of Neurological Disorders
CNS & Neurological Disorders - Drug Targets A High Burden of Ischemic Stroke in Regions of Eastern/Central Europe is Largely Due to Modifiable Risk Factors
Current Neurovascular Research Vasorelaxant and Antihypertensive Effects of <i>Mentha pulegium</i> L. in Rats: An In vitro and In vivo Approach
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Hybrid Anticonvulsants Derived from Pyrrolidine-2,5-dione Scaffold with Broad Spectrum of Activity in the Preclinical Studies
Current Topics in Medicinal Chemistry Immune Functions of Glia and Neurons in the Central Nervous System
Current Immunology Reviews (Discontinued) A Review on the Recent Trends in Synthetic Strategies and Applications of Xanthene Dyes
Mini-Reviews in Organic Chemistry A Review of Monoamine Transporter-Ligand Interactions
Current Computer-Aided Drug Design The Potential of Natural Products as Effective Treatments for Allergic Inflammation: Implications for Allergic Rhinitis
Current Topics in Medicinal Chemistry There is a Link Between Erectile Dysfunction and Heart Failure: It could be Inflammation
Current Drug Targets The Plasticity of the 7TMR Signaling Machinery and the Search for Pharmacological Selectivity
Current Pharmaceutical Design The Classic Basic Protein of Myelin – Conserved Structural Motifs and the Dynamic Molecular Barcode Involved in Membrane Adhesion and Protein-Protein Interactions
Current Protein & Peptide Science New Classes of AChE Inhibitors with Additional Pharmacological Effects of Interest for the Treatment of Alzheimers Disease
Current Pharmaceutical Design Molecular Mechanisms of Anti-Inflammatory Activity Mediated by Flavonoids
Current Medicinal Chemistry A Computational Framework to Identify Cross Association Between Complex Disorders by Protein-protein Interaction Network Analysis
Current Bioinformatics